Developer docs
API playgroundTry for free, no card

Search company profiles

Akers Biosciences

Full company profile

uuid0006q7l

Namestring
Akers Biosciences
Company typeenum
Private
Founded yearint
1989
Short descriptiontext

Akers Biosciences is a former NASDAQ-listed biotech (Thorofare, NJ) that pivoted from breath-analysis diagnostics to developing novel vaccine candidates for global health challenges; the company is now effectively dormant, delisted, with its website parked.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersThorofare, United States
HQ citystring
Thorofare
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
diagnostic breath tests, novel vaccine candidates, rapid diagnostic devices, biotechnology products, medical device manufacturing
Industry2 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology
Social media profiles2 records
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Akers Biosciences was a biotechnology company dedicated to solving global health challenges, with a focus on developing novel vaccine candidates. Historically, the company was also associated with the breathalyzer/breath analysis market, developing rapid diagnostic breath tests for health and safety applications. The company's website is currently parked and not operational, indicating the company is no longer actively operating its primary web presence.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Novel Vaccine Candidates
2Breath Diagnostic Tests
No data
Peers8 records
1Abbott Laboratories
TypeBroad incumbent
Description

Diversified global healthcare company with a broad diagnostics portfolio including point-of-care breath analysis. Comparable to Akers' legacy diagnostics business as a broad incumbent with overlapping capabilities.

TypeDirect peer
Description

Clinical-stage biotechnology company developing novel vaccines and immunotherapies against infectious diseases and cancer. Comparable in scale and focus to Akers' vaccine candidate pipeline positioning.

TypeDirect peer
Description

Clinical-stage biotechnology company developing oral recombinant vaccines delivered by tablet. A similarly small, single-focus vaccine developer targeting global health challenges — closely aligned with Akers' described mandate.

TypeDirect peer
Description

Specialty manufacturer of professional breath alcohol testing devices, comparable to Akers' legacy breath-analysis product line. A direct peer in the historical breathalyzer business.

TypeDirect peer
Description

Clinical-stage vaccine developer with a platform approach to novel vaccine candidates, including recombinant protein and nanoparticle vaccines. Directly comparable to Akers' stated focus on novel vaccine development, although operating at vastly larger scale.

6Drägerwerk
TypeBroad incumbent
Description

German medical and safety technology company historically competing in the breathalyzer market alongside Akers. Relevant as a peer given Akers' legacy business in breath-analysis devices prior to its vaccine pivot.

TypeDirect peer
Description

Manufacturer of breath alcohol testing instruments, historically cited as a competitor in the breath-analysis market Akers once addressed. Relevant as a legacy-business peer from Akers' pre-pivot commercial era.

TypeDirect peer
Description

Biopharmaceutical company focused on developing and commercializing novel vaccines, including its CpG 1018 adjuvant used in hepatitis B and COVID-19 vaccines. Comparable to Akers as a small-cap vaccine-focused biotech.

Market position
Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Akers Biosciences

Akers Biosciences is a former NASDAQ-listed biotech (Thorofare, NJ) that pivoted from breath-analysis diagnostics to developing novel vaccine candidates for global health challenges; the company is now effectively dormant, delisted, with its website parked.

Akers Biosciences firmographics

Firmographics
Name
Akers Biosciences
Website
https://akersbiosciences.com
Company type
Private
Founded year
1989
Operating status
Closed
Headcount range
11–50 employees
Short description
Akers Biosciences is a former NASDAQ-listed biotech (Thorofare, NJ) that pivoted from breath-analysis diagnostics to developing novel vaccine candidates for global health challenges; the company is now effectively dormant, delisted, with its website parked.
Ownership category
akta.pro rank

Akers Biosciences industry classification

Industry
Product category
Biotechnology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals

Keywords

  • Diagnostic breath tests
  • Novel vaccine candidates
  • Rapid diagnostic devices
  • Biotechnology products
  • Medical device manufacturing

Where Akers Biosciences is headquartered

Location

Headquarters

HQ city
Thorofare
HQ country
United States
HQ region
North America

Markets served

Akers Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Akers Biosciences product offering

Product offering

Core offering

Akers Biosciences was a biotechnology company dedicated to solving global health challenges, with a focus on developing novel vaccine candidates. Historically, the company was also associated with the breathalyzer/breath analysis market, developing rapid diagnostic breath tests for health and safety applications. The company's website is currently parked and not operational, indicating the company is no longer actively operating its primary web presence.

Differentiator

Problem solved

Functional benefit

Products and services

  • Novel Vaccine Candidates
  • Breath Diagnostic Tests

Companies that use Akers Biosciences

Customer profile

Ideal customer profiles2 records

Akers Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Akers Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Abbott Laboratories: Diversified global healthcare company with a broad diagnostics portfolio including point-of-care breath analysis. Comparable to Akers' legacy diagnostics business as a broad incumbent with overlapping capabilities.
  • Drägerwerk: German medical and safety technology company historically competing in the breathalyzer market alongside Akers. Relevant as a peer given Akers' legacy business in breath-analysis devices prior to its vaccine pivot.

Direct peers

  • GeoVax Labs: Clinical-stage biotechnology company developing novel vaccines and immunotherapies against infectious diseases and cancer. Comparable in scale and focus to Akers' vaccine candidate pipeline positioning.
  • Vaxart: Clinical-stage biotechnology company developing oral recombinant vaccines delivered by tablet. A similarly small, single-focus vaccine developer targeting global health challenges — closely aligned with Akers' described mandate.
  • Lifeloc Technologies: Specialty manufacturer of professional breath alcohol testing devices, comparable to Akers' legacy breath-analysis product line. A direct peer in the historical breathalyzer business.
  • Novavax: Clinical-stage vaccine developer with a platform approach to novel vaccine candidates, including recombinant protein and nanoparticle vaccines. Directly comparable to Akers' stated focus on novel vaccine development, although operating at vastly larger scale.
  • Intoximeters: Manufacturer of breath alcohol testing instruments, historically cited as a competitor in the breath-analysis market Akers once addressed. Relevant as a legacy-business peer from Akers' pre-pivot commercial era.
  • Dynavax Technologies: Biopharmaceutical company focused on developing and commercializing novel vaccines, including its CpG 1018 adjuvant used in hepatitis B and COVID-19 vaccines. Comparable to Akers as a small-cap vaccine-focused biotech.

Market position

Customer concentration

Akers Biosciences social profiles

Digital presence

Akers Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Akers Biosciences leadership team

Management profile

Number of profiles

Profiles5 records

Akers Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Akers Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akers Biosciences

What does Akers Biosciences do?

Akers Biosciences was a biotechnology company dedicated to solving global health challenges, with a focus on developing novel vaccine candidates. Historically, the company was also associated with the breathalyzer/breath analysis market, developing rapid diagnostic breath tests for health and safety applications. The company's website is currently parked and not operational, indicating the company is no longer actively operating its primary web presence.

When was Akers Biosciences founded?

Akers Biosciences was founded in 1989. It employs 11 to 50 people.

Where is Akers Biosciences based?

Akers Biosciences is headquartered in Thorofare, United States, in the North America region.

Who are Akers Biosciences's main competitors?

Broad incumbents on record are Abbott Laboratories and Drägerwerk. Direct peers are GeoVax Labs, Vaxart, Lifeloc Technologies, Novavax, Intoximeters and Dynavax Technologies.

Does Akers Biosciences have an API?

No public API is recorded for Akers Biosciences.

What industry is Akers Biosciences in?

Akers Biosciences's product category is Biotechnology. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSHAREHOLDER ALERT: WeissLaw LLP Reminds TLRY, CBLI, AKER and OBLN Shareholders About Its Ongoing InvestigationsWeissLaw LLP is investigating potential breaches of fiduciary duty by the boards of Tilray, Inc., Cleveland BioLabs, Inc., Akers Biosciences, Inc., and Obalon Therapeutics, Inc. related to their respective proposed mergers. These investigations focus on how the mergers may affect shareholder ownership and rights in each case.BenzingaAkers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated BiomarkerAkers Biosciences and its proposed merger partner MyMD Pharmaceuticals announced new study data showing their drug candidate MYMD-1 demonstrated inhibition of key biomarkers associated with fibrotic diseases, specifically transforming growth factor-beta and tumor necrosis factor. The research, conducted at Eurofins Discovery Phenotypic Center of Excellence, indicated MYMD-1's potential to limit fibrotic biology linked to idiopathic pulmonary fibrosis. MyMD plans to advance testing by combining MYMD-1 with approved fibrosis drugs, while the two companies continue working toward completing their merger agreement originally announced in November.PR NewswireSHAREHOLDER ALERT: WeissLaw LLP Reminds HLIX, XLNX, SNSS, and AKER Shareholders About Its Ongoing InvestigationsWeissLaw LLP announced ongoing investigations into four companies regarding potential breaches of fiduciary duty and other legal violations in connection with proposed mergers: Helix Technologies (HLIX) merging into a new entity called Forian Inc. via Medical Outcomes Research Analytics; Xilinx (XLNX) being acquired by Advanced Micro Devices (AMD); Sunesis Pharmaceuticals (SNSS) merging with Viracta Therapeutics; and Akers Biosciences (AKER) merging with privately-held MyMD Pharmaceuticals. The law firm is contacting shareholders of these companies to discuss their rights or interests in relation to these transactions.BenzingaWhy These 4 Pharma Stocks Are Moving TodayShares of four pharmaceutical companies moved significantly on Wednesday due to distinct corporate developments: Akers Biosciences rose 5% following a patent announcement by merger partner MyMD Pharmaceuticals, while Mesoblast gained 4.63% after receiving FDA fast-track designation for its Remestercel-L treatment. Conversely, Allena Pharmaceuticals and Auris Medical saw their stocks drop by 9.77% and 34.03% respectively, driven by equity offerings of $13 million and $8 million.PR NewswireWeissLaw LLP Reminds ALSK, EIGI, AKER, and TNAV Shareholders About Its Ongoing InvestigationsWeissLaw LLP issued investor notices on November 19, 2020, announcing investigations into possible breaches of fiduciary duty by the boards of directors of four companies in connection with proposed acquisitions or mergers. The four transactions include the acquisition of Alaska Communications Systems Group by Macquarie Capital and GCM Grosvenor for $3.00 per share, the acquisition of Endurance International Group Holdings by Clearlake Capital Group for $9.50 per share, the merger of Akers Biosciences with privately-held MyMD Pharmaceuticals, and the interested-party acquisition of Telenav by V99, Inc. led by TNAV's own President and CEO HP Jin for $4.80 per share. The firm is examining whether these transactions adequately protect shareholder interests, particularly noting concerns that the TNAV acquisition may significantly undervalue the company given the inherent conflicts of interest.PR NewswireSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Akers Biosciences, Inc. - AKERMonteverde & Associates PC, a securities litigation law firm, announced an investigation into Akers Biosciences, Inc. (AKER) regarding its proposed merger into MyMD Pharmaceuticals, under which Akers shareholders would receive only 20% ownership in the combined entity. The investigation will examine whether Akers and its Board violated securities laws or breached fiduciary duties by failing to conduct a fair process and potentially undervaluing the Company. Shareholders of Akers seeking additional information or to protect their investments can contact the firm at no cost.PR NewswireRM LAW Announces Investigation of Akers Biosciences, Inc.RM LAW, P.C. announced an investigation into potential breaches of fiduciary duties by the board of directors of Akers Biosciences, Inc., related to its proposed merger with MYMD Pharmaceuticals, Inc. The transaction involves Akers shareholders owning approximately 20% and MYMD shareholders owning approximately 80% of the combined entity upon completion.PR NewswireMoore Kuehn Encourages CGIX, AKER, TGC and DNKN Investors to Contact Law FirmMoore Kuehn, a New York securities litigation law firm, announced investigations into four proposed mergers: Cancer Genetics being acquired by StemoniX, Akers Biosciences being acquired by MYMD Pharmaceuticals, Tengasco merging with Riley Exploration-Permian, and Dunkin' Brands being acquired by Inspire Brands for $106.05 per share. The law firm is examining whether the boards of these companies acted to maximize shareholder value, disclosed material information, and conducted fair processes. The investigations concern allegations of potentially unfair terms, inadequate prices, and incomplete disclosure in merger solicitation statements filed with the SEC.BenzingaWhy Akers Biosciences Stock Is Trading Higher TodayAkers Biosciences and MyMD Pharmaceuticals signed a definitive merger agreement on Thursday, causing Akers Biosciences shares to surge 29.72% to $2.23. Akers Biosciences develops and supplies rapid point-of-care diagnostic screening and testing products for healthcare fields including cardiology, diabetes, and infectious disease detection, with the majority of its revenue coming from the United States.